Policies to drive biosimilar uptake may have ‘unintended consequences’, experts warn


The Pharmaceutical Benefits Advisory Committee (PBAC) will become gatekeeper in the government’s new push to increase the uptake of biosimilars. From July 1, two new policies outlined in the latest five-year agreement between the federal government and Medicines Australia will empower the PBAC to recommend differential prescribing rules for biosimilars and reference biologics. There are currently three ...


Already a member? Login to keep reading


OR
© 2017 the limbic